Laddar populära aktier...
Redeye comments on GiG ahead of its Q1-results (due 7 May) where we expect continued solid performan...
Solteq’s Q1 was weaker than expected and further cost savings are sought.
Etteplan publishes its Q1 results on 8th of May. We expect year-on-year revenue growth boosted by ac...
'24e-'26e EBITA down 7-1%... ...primarily due to changes in capitalisation policy '24e-'25e lease ad...
Q1e: still some de-stocking weighing on Medical Minor revisions, '25e-'26e EBITA up by 1% on FX Stro...
M&A to drive growth while organically flat, EBITA margin to hold up H1 weakness in EMS industry, but...
Ahead of Taaleri's Q1 results, due on 7 May, we adjust our Q1 estimates to reflect expected fair val...
Orviglance meets the primary endpoint in the SPARKLE study with a p-value of
Relais’ Commercial vehicle repair and maintenance company Raskone announced today acquisition of Ase...
STENOCARE published on May 2 the company’s Q1-report for 2024, showing progress.
Redeye briefly comments on Enviro’s press release, which stated that Enviro has received a second pa...
Sales -2% vs. ABGSCe, -7% y-o-y Ework expects sales to decline H1'24 but to recover in H2'24 We expe...
Q1 var utmanande med svag efterfrågan och omsättningen minskade.
Redeye presents its preview for Devyser’s Q1 2024 report, which is due on May 8.
Q1 2024 profit before loan losses came in at DKK 70m, DKK 4m (6%) ahead of our estimate.